Association of an apolipoprotein E polymorphism with circulating cholesterols and hypertension: A meta-based Mendelian randomization analysis

Hypertension Research

Volumn 35, Issue 4, 2012, Pages 434-440

  Niu, Wenquan ^a,b   Zhang, Xuezhi ^c   Qi, Yue ^d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Institute of Hypertension   (China)

^c China Petrochemical Corporation   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

apolipoprotein E; causality; Mendelian randomization; polymorphism

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALLELE; ARTICLE; ASIAN; CHOLESTEROL BLOOD LEVEL; DNA POLYMORPHISM; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; HYPERTENSION; MENDELIAN RANDOMIZATION ANALYSIS; META ANALYSIS; PREDICTOR VARIABLE;

ALLELES; APOLIPOPROTEINS E; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; LIPOPROTEINS, LDL; MENDELIAN RANDOMIZATION ANALYSIS; POLYMORPHISM, GENETIC;

EID: 84859594967     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.202     Document Type: Article

References (49)

1. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Borgioni C, Filippucci L, Poeta F, Porcellati C. Prognostic value of lipoprotein fractions in essential hypertension. Blood Press 2004; 13: 295-303. (Pubitemid 39555455)
2. Sesso HD, Buring JE, Chown MJ, Ridker PM, Gaziano JM. A prospective study of plasma lipid levels and hypertension in women. Arch Intern Med 2005; 165: 2420-2427. (Pubitemid 41640856)
3. Halperin RO, Sesso HD, Ma J, Buring JE, Stampfer MJ, Gaziano JM. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006; 47: 45-50. (Pubitemid 43177814)
4. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004; 33: 30-42. (Pubitemid 38528650)
5. Sheehan NA, Didelez V, Burton PR, Tobin MD. Mendelian randomisation and causal inference in observational epidemiology. PLoS Med 2008; 5: e177.
6. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, Gaziano JM, Liu S. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009; 361: 1152-1163.
7. Thomas DC, Conti DV. Commentary: the concept of 'Mendelian Randomization'. Int J Epidemiol 2004; 33: 21-25.
8. Sorlí JV, Corella D, Francés F, Ramírez JB, González JI, Guillén M, Portolés O. The effect of the APOE polymorphism on HDL-C concentrations depends on the cholesterol ester transfer protein gene variation in a Southern European population. Clin Chim Acta 2006; 366: 196-203. (Pubitemid 43330983)
9. Maluf DG, Mas VR, Archer KJ, Yanek K, King A, Ferreira-Gonzalez A, Fisher RA, Posner M. Apolipoprotein E genotypes as predictors of high-risk groups for developing hyperlipidemia in kidney transplant recipients undergoing sirolimus treatment. Transplantation 2005; 80: 1705-1711. (Pubitemid 43053995)
10. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011; 10: 241-252.
11. Abboud S, Viiri LE, Lütjohann D, Goebeler S, Luoto T, Friedrichs S, Desfontaines P, Gazagnes MD, Laloux P, Peeters A, Seeldrayers P, Lehtimaki T, Karhunen P, Pandolfo M, Laaksonen R. Associations of apolipoprotein E gene with ischemic stroke and intracranial atherosclerosis. Eur J Hum Genet 2008; 16: 955-960.
12. Ruixing Y, Jinzhen W, Weixiong L, Yuming C, Dezhai Y, Shangling P. The environmental and genetic evidence for the association of hyperlipidemia and hypertension. J Hypertens 2009; 27: 251-258.
13. Niu W, Qi Y, Qian Y, Gao P, Zhu D. The relationship between apolipoprotein E epsilon2/epsilon3/epsilon4 polymorphisms and hypertension: a meta-analysis of six studies comprising 1812 cases and 1762 controls. Hypertens Res 2009; 32: 1060-1066.
14. Niu WQ, Qi Y. Meta-based evidence for apolipoprotein E ε2/ε3/ε4 polymorphism in association with hypertension among Chinese. J HumHypertens 2011 (Epub ahead of print).
15. Shiwaku K, Gao TQ, Hojo N, Fukushima T, Yamane Y. Low levels of serum cholesterol and systolic blood pressure in Japanese with the apolipoprotein E3/2 genotype. Clin Chim Acta 1999; 284: 15-23. (Pubitemid 29324861)
16. Rastas S, Mattila K, Verkkoniemi A, Niinistö L, Juva K, Sulkava R, Länsimies E. Association of apolipoprotein E genotypes, blood pressure, blood lipids and ECG abnormalities in a general population aged 85+. BMC Geriatr 2004; 4: 1.
17. Niu W, Guo X, Su Y, Qiu C. Apolipoprotein E and low-density lipoprotein receptor gene polymorphisms in dyslipidemias-associated essential hypertension. J Hum Hypertens 2007; 21: 337-339. (Pubitemid 46443598)
18. Egert S, Boesch-Saadatmandi C, Wolffram S, Rimbach G, Müller MJ. Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr 2010; 140: 278-284.
19. Cohn LD, Becker BJ. How meta-analysis increases statistical power. Psychol Methods 2003; 8: 243-253. (Pubitemid 37268945)
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558. (Pubitemid 34746062)
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ 2003; 327: 557-560.
22. Little J, Khoury MJ. Mendelian randomisation: a new spin or real progress? Lancet 2003; 362: 930-931. (Pubitemid 37159286)
23. Davey Smith G, Ebrahim S. Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32: 1-22. (Pubitemid 36503465)
24. Imazu M, Yamamoto H, Toyofuku M, Watanabe T, Okubo M, Egusa G, Yamakido M, Kohno N. Association of apolipoprotein E phenotype with hypertension in Japanese- Americans: data from the Hawaii-Los Angeles-Hiroshima Study. Hypertens Res 2001; 24: 523-529. (Pubitemid 33048918)
25. Yilmaz H, Isbir T, A∂açhan B, Aydin M. Is epsilon4 allele of apolipoprotein E associated with more severe end-organ damage in essential hypertension? Cell Biochem Funct 2001; 19: 191-195. (Pubitemid 32768768)
26. Li X, Du Y, Du Y, Huang X. Association of apolipoprotein E gene polymorphism with essential hypertension and its complications. Clin Exp Med 2003; 2: 175-179. (Pubitemid 36313183)
27. Bhavani AB, Sastry KB, Reddy NK, Padma T. Lipid profile and apolipoprotein E polymorphism in essential hypertension. Indian Heart J 2005; 57: 151-157. (Pubitemid 40992666)
28. Fuzikawa AK, Peixoto SV, Taufer M, Moriguchi EH, Lima-Costa MF. Association of ApoE polymorphisms with prevalent hypertension in 1406 older adults: the Bambuí Health Aging Study (BHAS). Braz J Med Biol Res 2008; 41: 89-94. (Pubitemid 351425848)
29. Hamulati W, Aisikaer Y, Yilihamujiang S. Relationship between ApoE gene polymorphism and patients of hypertension in Uighur. Chin J Immunol 2003; 19: 108-110.
30. Zhimian Z, Haiqing G, Qing S, Lihua F. Clinical study of relationship between ApoE gene polymorphism and hypertension in aged. Acta Academiae Medicinae Shandong 2000; 38: 173-176.
31. Caiyou H, Chenguang Z, Zeping L. The study of relation between blood pressure and apolipoprotein E genotypes in long-lived elderly in Bama area of Guangxi. Chin J Geriatr Heart Brain Vessel Dis 2007; 9: 11-13.
32. Weize Z, Xinghui L, Yongqing C. Relationship between apolipoprotein E gene polymorphism and essential hypertension in Han, Tibetan and Hui population in high altitude area. Chin Circ J 2007; 22: 263-266.
33. Chunli R, Yingxin P, Meixia L, Ruyi L, Xue G. Analysis of apolipoprotein E gene polymorphism in hypertensive patients. Shandong Med J 2007; 47: 29-30.
34. Yingwang L, Shuiping Z, An Z, Sai N. Effect of apolipoprotein E gene polymorphism on lipid and essential hypertension. Chin J Arterioscler 2002; 10: 517-520.
35. Wen P, Siming G, Wei L, Xiaohong Z. Apolipoprotein E gene polymorphism and hypertension. J Chin Gen Pract 2003; 2: 14-15.
36. Guofang C, Zhu M, Bingxian H. Relationships between polymorphism of apoE gene and hypertension in the Han ethnics of China. Chin J Clin Rehab 2003; 7: 2545-2546.
37. Min P, Jianhua Z, Li L. Association of Apolipoprotein E with essential hypertension, NIDDM and coronary heart disease in Chinese population. Chin Synth Med 2002; 3: 1-3.
38. Huaiqin Z, Weijian YKH, Jie L, Chengang S. To explore the relativity of apolipoprotein B and E gene polymorphism with coronary heart disease and hypertension. Prev Treat Cardio-Cerebral-Vasc Dis 2002; 2: 20-22.
39. Haiqing G, Junli Y, Zhimian Z, Qing S, Huanqin C, Yongle S, Guihua W. Clinical study on apolipoprotein E genetic polymorphism among elders. Chin J Geriatr 2002; 21: 299-300.
40. Kesäniemi YA, Ehnholm C, Miettinen TA. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest 1987; 80: 578-581.
41. Ciolac EG, Bocchi EA, Bortolotto LA, Carvalho VO, Greve JM, Guimarães GV. Haemodynamic, metabolic and neuro-humoral abnormalities in young normotensive women at high familial risk for hypertension. J Hum Hypertens 2010; 24: 814-822.
42. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8: 1-21. (Pubitemid 18049171)
43. Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN, Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 2001; 358: 115-119. (Pubitemid 32709850)
44. Brewer Jr HB, Zech LA, Gregg RE, Schwartz D, Schaefer EJ. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann Intern Med 1983; 98: 623-640. (Pubitemid 13091177)
45. Yang R, Powell-Braxton L, Ogaoawara AK, Dybdal N, Bunting S, Ohneda O, Jin H. Hypertension and endothelial dysfunction in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 1999; 19: 2762-2768. (Pubitemid 29536055)
46. Corella D, Guillén M, Sáiz C, Portolés O, Sabater A, Cortina S, Folch J, González JI, Ordovas JM. Environmental factors modulate the effect of the APOE genetic polymorphism on plasma lipid concentrations: ecogenetic studies in a Mediterranean Spanish population. Metabolism 2001; 50: 936-944. (Pubitemid 32755011)
47. Timpson NJ, Harbord R, Davey Smith G, Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. Does greater adiposity increase blood pressure and hypertension risk?: Mendelian randomization using the FTO/MC4R genotype. Hypertension 2009; 54: 84-90.
48. Smith GD, Harbord R, Milton J, Ebrahim S, Sterne JA. Does elevated plasma fibrinogen increase the risk of coronary heart disease? Evidence from a metaanalysis of genetic association studies. Arterioscler Thromb Vasc Biol 2005; 25: 2228-2233. (Pubitemid 41416326)
49. Pereira TV, Nunes AC, Rudnicki M, Yamada Y, Pereira AC, Krieger JE. Meta-analysis of the association of 4 angiotensinogen polymorphisms with essential hypertension: a role beyond M235T? Hypertension 2008; 51: 778-783. (Pubitemid 351301535)